Ethical relationships with healthcare professionals are critical to our mission of helping patients by developing and marketing new medicines.

In the era of data-driven medicine, where all parties seek more, not less, information about the safety, effectiveness, and value of treatments, fostering informed communications among all stakeholders is critical.

Emerging payment and delivery reforms (often called “alternative payment models” or “value-based payment” designs) hold promise in advancing the efficient delivery of high-quality, personalized care.

In July 2013, members of PhRMA and the European Federation of Pharmaceutical Industries and Associations (EFPIA) adopted Principles for Responsible Clinical Trial Data Sharing.

Healthcare providers and payers are increasingly turning to clinical pathways as tools to manage the cost of care and promote evidence-based treatment.